Tagged with IRA

Pharma The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international partnership strategy and how her diverse background in engineering, medicine and a variety of companies has equipped her to lead…

pharma  David Lenihan, CEO of Ponce Health Sciences University (PHSU), and Kenira Thompson, president of the Ponce Research Institute, highlight the institution’s pioneering efforts in creating cultural competency for medical graduates and increasing investments in clinical research from the US for large-scale trials. What are your perceptions of Puerto Rico’s research…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…

Pharma Tugce Gozacan (pictured) and Okan Gozacan, Owner and Chairman of Marmara Ecza respectively, discuss what qualities are crucial for suppliers in the pharmaceutical industry, their process for forming partnerships and attracting clients, and their vision for a future with Iran as a major player. As an introduction for our readers,…

pharma Ileana Quiñones, president and general manager of iPR-AstraZeneca, discusses the clear strategy of the affiliate in being a leading manufacturer in Puerto Rico and the steps necessary to ensure their place in the country and within the AstraZeneca organization. Where is AstraZeneca focused today and how does the Puerto Rican…

pharma The country president for South Africa & Sub-Saharan Africa at AstraZeneca reveals why AstraZeneca sees Africa as the next frontier within the pharmaceutical industry, how their Research Trust looks to contribute to academic advancement on the continent, with a focus on non-communicable diseases, and how their Healthy Heart Africa program…

Hospira Carolina López-Torres joined Hospira Peru in 2011 following a dynamic career at Novartis. She discusses the early challenges she faced and the opportunities that the government’s hospital expansion plan has provided the market leader for pumps in Peru. What was the initial mission given to you when you first arrived?…

respiratory disease The country manager of an Italian pharmaceutical firm talks about the evolution of Algerian health needs and what her firm is doing to counter different forms of respiratory disease prevalent in the country. After eighteen years at Chiesi, what have been your main successes to date? On a personal note,…

R&D Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui Santos explains this process and how he plans to tackle the tough Portuguese marketplace.   Almirall has been in Portugal…

Generics Armando Esguerra, President of Chira Pharmaceuticals, Philippines, explains the concept of chirality, why it is relevant and extremely important in the pharmaceutical industry, and what have been the major challenges and successes of the company since its founding.    CHIRA Pharmaceuticals as a company was founded on the concept of…

Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…